Merck & Co., Inc. (NYSE:MRK) Q4 2023 Earnings Conference Call February 1, 2024 9:00 AM ET Company Participants Peter Dannenbaum - Vice President, Investor Relations Rob Davis - Chairman and Chief Executive Officer Caroline Litchfield - Chief Financial Officer Dean Li - President, Merck Research Labs Conference Call Participants Umer Raffat - Evercore ISI Trung Huynh - UBS Daina Graybosch - Leerink Partners Carter Gould - Barclays Evan Seigerman - BMO Capital Markets Terence Flynn - Morgan Stanley Adam Jolly ...

Merck (MRK) reported $14.63 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 5.8%. EPS of $0.03 for the same period compares to $1.62 a year ago.The reported revenue represents a surprise of -0.45% over the Zacks Consensus Estimate of $14.7 billion. With the consensus EPS estimate being -$0.09, the EPS surprise was +133.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...

Merck & Co Inc (NYSE:MRK) announced surprise fourth-quarter profits of 3 cents per share earlier, as well as revenue of $14.63 billion, both of which easily surpassed analysts' expectations. Strong demand for cancer drug Keytruda, as well as its HPV vaccine Gardasil contributed to the upbeat results. MRK is up 2.4% to trade at $123.58 at last check, and earlier surged to an all-time high of $125.75. The shares are now on track for their fifth win in the last six trading sessions, with long-term support stem ...

Merck (MRK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $1.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 133.33%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $1.94 per share when it actually produced earnings of $2.13, delivering a surprise of 9.79%.Over the last four quarters ...

Merck & Co. Inc. on Thursday reported fourth-quarter earnings and sales that beat analysts’ expectations, powered by strong growth in cancer and vaccine products.  The drugmaker reported a net loss of $1.226 billion, or 48 cents a share, after income of $3.017 billion, or $1.18 a share, in the year-earlier period. Adjusted earnings came to 3 cents a share, down from $1.62 a year earlier but beating the FactSet consensus of a loss of 11 cents a share. Revenue totaled $14.63 billion in the quarter, up 6% from ...

The logo for Merck & Co. is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, New York, U.S., November 17, 2021.Merck on Thursday reported fourth-quarter revenue and adjusted earnings that topped estimates as it saw strong demand for its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. The pharmaceutical giant posted a net quarterly loss, however, due to previously announced charges associated with a deal the company struck in October with the Japanese drugmaker Dai ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. These late-breaking data are being presented during an oral session for the first time today at t ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced resectable urothelial carcinoma. These late-breaking data are being presented for the first time today during an oral abstract session at the 2024 Amer ...

We expect Merck (MRK) to beat expectations when it reports fourth-quarter and full-year 2023 results on Feb 1, before market open. In the last reported quarter, the company delivered an earnings surprise of 9.79%.Factors to ConsiderStrong global underlying demand across its business, particularly for cancer drug Keytruda and HPV vaccine Gardasil, is likely to have boosted sales growth in the fourth quarter like several previous quarters.In oncology, Keytruda sales are likely to have been driven by increased ...

On Jan. 8, pharmaceutical giant Merck (MRK 0.45%) moved to acquire biotech Harpoon Therapeutics, (HARP -0.76%) for $680 million in cash. The point of the acquisition, which should close in the first half of this year, is to gain access to Harpoon's technology and its pipeline of early-stage therapy candidates for various solid tumor cancers, including a pair that aim to treat small cell lung cancer and multiple myeloma.Overall, the move will bolster Merck's oncology pipeline directly, and it might also pave ...